Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs
暂无分享,去创建一个
[1] A. Strongin,et al. Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis , 2017, Scientific Reports.
[2] A. Stenzinger,et al. Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux. , 2017, International journal of antimicrobial agents.
[3] J. Dye,et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects , 2017, The Journal of clinical investigation.
[4] N. Gray,et al. GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. , 2016, Cell chemical biology.
[5] S. Ezzat,et al. Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4: a double-blind placebo-controlled trial , 2016, European journal of gastroenterology & hepatology.
[6] A. Butt,et al. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. , 2015, World journal of gastroenterology.
[7] Steven M. Opal,et al. Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers , 2015, mBio.
[8] Nicolas Stransky,et al. Targeting cancer with kinase inhibitors. , 2015, The Journal of clinical investigation.
[9] B. D. da Fonseca,et al. Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys. , 2015, Viral immunology.
[10] G. Kaplan,et al. Metformin as adjunct antituberculosis therapy , 2014, Science Translational Medicine.
[11] J. Rossignol. Nitazoxanide: A first-in-class broad-spectrum antiviral agent , 2014, Antiviral Research.
[12] C. Ginocchio,et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial , 2014, The Lancet Infectious Diseases.
[13] Julie Dyall,et al. Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.
[14] Michele Connelly,et al. Repositioning: the fast track to new anti-malarial medicines? , 2014, Malaria Journal.
[15] Anne E Carpenter,et al. Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium tuberculosis Growth , 2014, PLoS pathogens.
[16] B. D. da Fonseca,et al. Chloroquine use improves dengue-related symptoms , 2013, Memorias do Instituto Oswaldo Cruz.
[17] J. Tilton,et al. Entry inhibitors and their use in the treatment of HIV-1 infection. , 2013, Antiviral research.
[18] Priscilla L. Yang,et al. The Small Molecules AZD0530 and Dasatinib Inhibit Dengue Virus RNA Replication via Fyn Kinase , 2013, Journal of Virology.
[19] P. Gallay,et al. Curing a viral infection by targeting the host: The example of cyclophilin inhibitors , 2013, Antiviral Research.
[20] C. Nathan,et al. Efficacy of Nitazoxanide against Clinical Isolates of Mycobacterium tuberculosis , 2013, Antimicrobial Agents and Chemotherapy.
[21] Chengyu Jiang,et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model , 2012, Cell Research.
[22] J. Farrar,et al. Correction: A Randomized Controlled Trial of Chloroquine for the Treatment of Dengue in Vietnamese Adults , 2012, PLoS Neglected Tropical Diseases.
[23] D. Kalman,et al. Productive Replication of Ebola Virus Is Regulated by the c-Abl1 Tyrosine Kinase , 2012, Science Translational Medicine.
[24] R. Striker,et al. Phosphorylation events during viral infections provide potential therapeutic targets , 2011, Reviews in medical virology.
[25] D. Kalman,et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. , 2011, Cell host & microbe.
[26] Olivier Poch,et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy , 2011, Nature Medicine.
[27] H. Ellerbrok,et al. Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa). , 2011, Antiviral research.
[28] D. Kalman,et al. Variola and Monkeypox Viruses Utilize Conserved Mechanisms of Virion Motility and Release That Depend on Abl and Src Family Tyrosine Kinases , 2010, Journal of Virology.
[29] J. Farrar,et al. A Randomized Controlled Trial of Chloroquine for the Treatment of Dengue in Vietnamese Adults , 2010, PLoS neglected tropical diseases.
[30] M. Labow,et al. Cholesterol biosynthesis modulation regulates dengue viral replication. , 2009, Virology.
[31] P. Shi,et al. Cyclosporine Inhibits Flavivirus Replication through Blocking the Interaction between Host Cyclophilins and Viral NS5 Protein , 2009, Antimicrobial Agents and Chemotherapy.
[32] B. Klebl,et al. Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo. , 2008, Antiviral research.
[33] J. Millis,et al. Leflunomide for polyomavirus type BK nephropathy. , 2005, The New England journal of medicine.
[34] S. Huong,et al. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus , 2003, Nature.
[35] S. McOrist. Obligate intracellular bacteria and antibiotic resistance. , 2000, Trends in microbiology.
[36] D. Knight,et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. , 1999, Intervirology.
[37] B. Rosenwirth,et al. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions , 1995, Journal of virology.
[38] R. Baker,et al. Stage-selective inhibition of rodent malaria by cyclosporine , 1988, Antimicrobial Agents and Chemotherapy.